Sir, It was with great interest that we read the article on advanced access by Sevilla et al. (2015) regarding axonal Charcot-Marie-Tooth (CMT2) disease caused by mutations in the MORC2 gene. Through whole-exome sequencing in a Spanish four generation CMT2 family with autosomal dominant pattern of inheritance, the authors identified the mutation p.R190W in the MORC2 gene as the cause of the disease. It was the only variant detected by whole-exome sequencing that segregated with the disease in the family. Afterwards, they tested an additional 52 patients with axonal Charcot-Marie-Tooth and found mutations in the MORC2 gene in two additional families, one with different de novo mutation and the second with the same p.R190W mutation, also de novo.
Here, we would like to report another patient with the p.R190W mutation in the MORC2 gene and thus confirm the causality of this gene for the severe CMT2 with striking proximal weakness. Also, we would like to show that the p.R190W mutation is a hot spot and probably the most frequent mutation in this gene. Immediately after we became aware of this newly discovered gene, we detected this mutation by re-examining older whole-exome sequencing data in one of our patients. This observation may have consequences for clinical DNA diagnostics because the phenotype, despite being probably rare, seems to be clinically recognizable and selected patients may first be tested for this mutation. This study was approved by the ethics committee of University Hospital Motol and informed consent was obtained from the patient according to the Declaration of Helsinki.
A 39-year-old patient of Czech origin is a sporadic case in the family. He was born with a foot deformity-a prominent dorsal flexion of both feet-which later returned to normal at the age of 12 months. He reached early developmental milestones normally. The first signs of the disease occurred at the age of 6 and these were mainly frequent tripping due to foot and distal leg weakness, difficulties riding a bicycle or skiing. Diagnosis of axonal CharcotMarie-Tooth was first stated at the age of 10 years.
At examination at the age of 15 years he complained about difficulty with walking. At that time he was able to walk a maximum distance of 1500 m. Foot deformity, hammer toes and calluses on the external side of the foot were noticed. Moreover, he reported having poor handwriting, difficulty using zippers and buttons. Atrophies of thenar and hypothenar muscles and also forearm muscles were observed.
When he was 20 years old, he began using a cane, two canes when he was 23. From the age of 27, he has been confined to a wheelchair. Examination at 30 years of age showed progression of the disease. It is worth mentioning that overall muscle weakness was observed, with flexor muscles (including hip flexors) being weaker than extensor muscles. Clinical presentation is summarized in Table 1 . Photographs of the patient are shown in Fig. 1 . Nerve conduction studies results are summarized in Table 2 .
The patient has been tested, since 2001, for PMP22 duplication/deletion and Sanger sequencing of MPZ, MFN2 and GDAP1 genes were performed. In 2014 we targeted parallel sequencing with a gene panel of 72 genes, mutations of which were associated with inherited peripheral neuropathies. No significant variants that could explain the cause of CMT2 in this patient were found. Therefore, we sought to determine the genetic basis for CMT2 using exome sequencing. This was done with Agilent SureSelect Human All Exon V5 kit at the John P. Hussman Institute for Human Genomics in Miami, FL, USA. Data were analysed in Genesis application (formerly Gem.app; https://genomics. med.miami.edu/) (Gonzalez et al., 2015) . In the second step, data were analysed in SureCall software (Agilent, Santa Clara, CA, USA). Variants were annotated with GenomeTrax (http://www.biobase-international.com/product/genome-trax), AlamutBatch (Interactive Biosoftware, http://www.interactive-biosoftware.com/) and Annovar software (http://www.openbioinformatics.org/annovar/). Variants were filtered according to recommendations (MacArthur et al., 2014; Richards et al., 2015) . No variants that could explain the cause of the disease were found. The paper by Sevilla et al. (2015) was then published online, and we re-evaluated the whole-exome sequencing data from this patient and the p.R190W mutation was found.
The mutation c.568C4T (p.R190W) in the MORC2 gene (NM_014941.2) was confirmed with Sanger sequencing of exon 10 of the MORC2 gene in the patient, but not in his mother or his father, indicating the de novo origin of the mutation, similarly to that in Family fCMT-197 reported by Sevilla et al. (2015) . Maternity/paternity was tested with a set of 10 microsatellite markers and false paternity was not observed.
Considering all of this information together, we concluded that mutation p.R190W is pathogenic and causal for CMT2 in this patient. Moreover, de novo occurrence of the mutation in our patient, but also in a Spanish family, suggest that p.R190W is a mutational hot spot and the most frequent mutation in this gene and that the occurrence in two of the three reported families in the Sevilla et al. (2015) paper is not by chance.
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